Compare PBBK & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBBK | ACXP |
|---|---|---|
| Founded | 1919 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.5M | 6.8M |
| IPO Year | N/A | 2021 |
| Metric | PBBK | ACXP |
|---|---|---|
| Price | $19.81 | $2.95 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $143.67 |
| AVG Volume (30 Days) | 10.8K | ★ 59.4K |
| Earning Date | 02-25-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.39 | N/A |
| EPS | ★ 0.98 | N/A |
| Revenue | ★ $13,918,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $20.21 | ★ N/A |
| Revenue Growth | ★ 17.20 | N/A |
| 52 Week Low | $14.23 | $2.44 |
| 52 Week High | $22.92 | $21.00 |
| Indicator | PBBK | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 39.63 |
| Support Level | $21.04 | $2.44 |
| Resistance Level | $21.95 | $3.54 |
| Average True Range (ATR) | 0.54 | 0.24 |
| MACD | -0.21 | 0.01 |
| Stochastic Oscillator | 9.43 | 43.19 |
PB Bankshares Inc follows a community bank model and provides multiple services to individuals and small to midsize businesses. Its business consists of attracting retail and commercial deposits from the general public in its market area and investing those deposits, together with funds generated from operations and borrowings, in commercial real estate loans, commercial and industrial loans, construction, home equity lines of credit and to a lesser extent, one- to four-family residential real estate loans and consumer loans.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.